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Background: Intracerebral hemorrhage is the most feared complication of intravenous thrombolysis for acute
ischemic stroke. Such hemorrhage usually occurs within or at the margin of ischemic or manifestly infarcted brain
tissue. A patient with Trousseau syndrome who developed multiple extra-ischemic hemorrhages following intravenous
thrombolysis is described.
Case description: An 80-year-old Japanese man with no other underlying disease was diagnosed with unresectable
advanced lung cancer (stage IV) without brain metastasis and had not yet been treated. The patient suddenly presented
with disturbance of consciousness, right hemiplegia, and total aphasia, and was admitted to our hospital. Magnetic
resonance imaging revealed acute cerebral infarction extending from the basal ganglia to the corona radiata of the left
cerebrum and multiple small areas of bilateral cerebral cortices. Cardiogenic cerebral embolism was considered among
the differential diagnoses, but the brain natriuretic peptide level was within the normal range, and no arrhythmias such as
atrial fibrillation were observed. With no other causes, the patient was diagnosed with Trousseau syndrome due
to hypercoagulability associated with the advanced lung cancer. The patient received intravenous tissue plasminogen
activator (t-PA) at 96 minutes after onset of symptoms. His symptoms partially improved, but they suddenly deteriorated
at 84 minutes after the thrombolysis. A computed tomography (CT) scan immediately after the neurological deterioration
revealed a subcortical hemorrhage in the left occipital lobe. A repeat CT scan the day after onset showed enlargement
of the left occipital hemorrhage and two new subcortical hemorrhages in the right frontal and right temporal lobes.
These hemorrhages were located in areas remote from the acute ischemic lesions.
Conclusion: To the best of our knowledge, this is the first reported case of multiple extra-ischemic hemorrhages
following intravenous thrombolysis in a patient with Trousseau syndrome. The course of this case suggests that
intravenous t-PA administration for acute ischemic stroke with Trousseau syndrome may be associated with a
higher risk of intracranial hemorrhage.
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Although treatment with intravenous tissue plasminogen
activator (t-PA) improves clinical outcomes in carefully
selected patients with acute ischemic stroke, intracerebral
hemorrhage is the most feared complication of this treat-
ment (No authors 1995). Incidence rates of symptomatic
intracranial hemorrhage have been reported to account* Correspondence: rocky@kuhp.kyoto-u.ac.jp
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thrombolysis in some clinical studies (Albers et al. 2000;
Hill and Buchan 2005; Wahlgren et al. 2007). The majority
of such hemorrhages occur within or at the margin of
ischemic or manifestly infarcted brain tissue (Wahlgren
et al. 2007). Meanwhile, intracerebral hemorrhage can also
appear in brain tissue without apparent acute ischemia,
and the incidence of extra-ischemic hemorrhages has been
reported at 1.3-3.7% of acute ischemic stroke following
intravenous thrombolysis (No authors 1997; Trouillas and
von Kummer 2006; Wahlgren et al. 2007). Intra- andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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partly different underlying pathophysiological mechanisms
(Mazya et al. 2014).
In 1865, Trousseau described migratory thrombosis as
the first manifestation of occult gastric cancer (Rickles
and Edwards 1983). Since then, the association between
cancer and excessive blood coagulation has remained
well-recognized. The description of Trousseau syndrome
was refined and reported as being frequently associated
with chronic disseminated intravascular coagulation,
plate-rich microthrombi, macroangiopathic hemolytic
anemia, verrucous endocarditis, and thromboembolic
problems related to these processes (Sack et al. 1977).
Uchiyama et al. described that Trousseau syndrome is a
paraneoplastic neurologic syndrome caused by remote
effects of occult cancers, which causes neurological
symptoms due to hypercoagulability associated with can-
cers (Uchiyama and Shimizu 2003). Today, the concept
of Trousseau syndrome is commonly used not only to
describe migratory thrombosis that precedes the diagnosis
of occult cancer, but also any hypercoagulability associated
with malignant cancer (Varki 2007). Thus, when acute is-
chemic strokes occur in patients with cancer, Trousseau
syndrome should be considered in the differential diagno-
sis. In the current American Heart Association/American
Stroke Association guidelines, intravenous t-PA adminis-
tration in acute ischemic stroke associated with Trousseau
syndrome is not mentioned (Jauch et al. 2013). To the
best of our knowledge, this is the first reported case of
multiple extra-ischemic hemorrhages following intra-
venous t-PA in a patient with Trousseau syndrome.
Case description
An 80-year-old Japanese man with no other underlying
disease had a chief complaint of cough, and chest radi-
ography showed an abnormal shadow in the right lung.
He was referred to our hospital for diagnosis and treat-
ment. A 9-cm lesion was observed in the right lower
lobe on contrast-enhanced computed tomography (CT)
of the chest. Transbronchial lung biopsy showed this to
be adenocarcinoma 24 days before the onset of cerebral
infarction. Metastases to ipsilateral hilar lymph nodes,
liver, and the left kidney were suggested by contrast-
enhanced CT of the trunk, and he was determined to
have stage IV advanced lung cancer. Brain metastasis
was not detected on head gadolinium-enhanced mag-
netic resonance imaging (MRI) 15 days before the onset
of cerebral infarction. Since a curative operation was
impossible, he was scheduled to be treated with systemic
chemotherapy. However, he developed a sudden disturb-
ance of consciousness, right hemiplegia, and total aphasia
while walking outdoors, and he was admitted to our
hospital 32 minutes after the onset of symptoms. His
temperature was 36.8°C, blood pressure was 125/68 mmHg,and heart rate was 82 beats/min with no atrial fibrillation.
His initial National Institutes of Health Stroke Scale
(NIHSS) score was 26. His complete blood counts were as
follows: white blood cell count 5400 /μL, red blood cell
count 3,520,000 /μL, hemoglobin 10.8 g/dL, and platelets
196,000 /μL. The coagulation system showed activation, with
a fibrinogen level of 629 mg/dL (normal 200–400 mg/dL),
a D-dimer level of 6.02 μg/mL (normal: 0–0.99 μg/mL), and
a fibrin degradation product level of 15 μg/mL (normal:
0–5 μg/mL), with a prothrombin time of 13.6 s (normal:
10–12 s; prothrombin time international ratio of 1.15) and
an activated partial thromboplastin time of 32.5 s (normal:
24–39 s). Cardiogenic cerebral embolism was considered
in the differential diagnosis, but the brain natriuretic
peptide level was 17.2 pg/mL (normal: 0–18.4 pg/mL),
which was within the normal range. The other blood
biochemical test results were not abnormal except for
elevated C-reactive protein (8.73 mg/dL). He was not
diagnosed with disseminated intravascular coagulation
based on the clinical and laboratory information. Chest
radiography did not show any enlargement of the superior
mediastinal shadow or cardiac shadow. Diffusion-weighted
imaging (DWI) showed a high-intensity area extending
from the basal ganglia to the corona radiata of the left
cerebrum and multiple small high-intensity areas at
bilateral cerebral cortices (Figure 1A). Among these acute is-
chemic lesions, some showed hyper-intensity signals on fluid-
attenuated inversion recovery (FLAIR) imaging (Figure 1B).
T2*-weighted imaging did not demonstrate hypointense sig-
nal areas or spots that suggested cerebral microbleeds.
Magnetic resonance angiography (MRA) demonstrated no
steno-occlusive changes in cerebral arteries (Figure 1C).
Although the long-term prognosis of the lung cancer
was considered poor, the patient received 0.6 mg/kg of
intravenous t-PA starting 96 minutes after onset of
symptoms because of no identifiable contraindications.
His symptoms improved partially (NIHSS score: 18), but
he suddenly became stuporous at 84 minutes after the
intravenous t-PA (NIHSS score: 25). Blood pressure was
134/72 mmHg with a heart rate of 76 beats/min at the
time. A CT scan immediately after the neurological
deterioration showed a subcortical hemorrhage in the
left occipital lobe (Figure 2A). A repeat CT scan the day
after onset showed enlargement of the left occipital
hemorrhage and two new subcortical hemorrhages in
the right frontal and right temporal lobes (Figure 2B).
These three intracerebral hemorrhages were located in
extra-ischemic areas that were remote from the acute is-
chemic lesions detected on DWI. The patient was given
conservative treatment for the intracranial hemorrhages
due to the poor prognosis for the primary disease. Four-
teen days of electrocardiographic monitoring conducted
after the ischemic stroke did not show arrhythmias such
as atrial fibrillation. Transthoracic echocardiography and
Figure 1 Head magnetic resonance imaging after onset. A: Diffusion-weighted image (DWI) showing a high-intensity area extending from
the basal ganglia to the corona radiata of the left cerebrum and multiple small high-intensity areas at bilateral cerebral cortices. B: Fluid-attenuated
inversion recovery showing several small high-intensity areas in the same locations detected on DWI (arrowheads). C: Magnetic resonance angiography
demonstrating no steno-occlusive changes.
Ikeda et al. SpringerPlus  (2015) 4:141 Page 3 of 5venous ultrasonography of the lower limbs were con-
ducted to search for the source of embolism, but did
not show any abnormalities. Despite the presence of
hypercoagulability and suspected cerebral embolism,
neither source of embolism nor obvious factor wasFigure 2 Head computed tomography (CT) scans after thrombolysis.
hemorrhage in the left occipital lobe. B: Repeat CT scan the day after onset sh
hemorrhages in the right frontal and right temporal lobes.found. Therefore, he was diagnosed as having Trous-
seau syndrome associated with advanced lung cancer.
Systemic chemotherapy and anticoagulant therapy were
not performed. He was discharged home 66 days after
admission with a modified Rankin Scale score of 5, andA: CT scan right after the neurological deterioration showing a subcortical
owing enlargement of the left occipital hemorrhage and two subcortical
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ischemic stroke. The autopsy was not performed.
Discussion and evaluation
There are many causes of thrombosis in Trousseau syn-
drome associated with cancer because the pathogenesis
of Trousseau syndrome is complex; cancer itself often
causes the underlying mechanism. When cells of the
monocyte or macrophage lineage interact with malignant
cells, they release tumor necrosis factor, interleukin-1, and
interleukin-6. These cytokines cause endothelial damage
and sloughing of endothelial cells and thereby promote
thrombosis (Bick 2003). The interaction between tumor
cells and macrophages also activates platelets, factor VII,
and factor X, which leads to the generation of thrombin
and thrombosis (Bick 2003). Trousseau syndrome often
occurs with mucinous adenocarcinomas such as lung,
pancreatic, and ovarian cancers (Sutherland et al. 2003).
Circulating carcinoma mucins interacting with leukocyte
L-selectin and platelet P-selectin generate platelet aggrega-
tion without requiring accompanying thrombin generation
(Wahrenbrock et al. 2003). Mucins from adenocarcinomas
also cause nonenzymatic activation of factor X (Bick 2003).
Treatment with intravenous t-PA for acute ischemic
stroke is associated with an increased risk of intracerebral
hemorrhage. Symptomatic intracerebral hemorrhages
following intravenous thrombolysis are associated with
several factors, including older age, increased stroke sever-
ity, higher glucose level, prior antiplatelet use, presence of
atrial fibrillation, congestive heart failure, renal impair-
ment and extent of early ischemic changes (Dzialowski
et al. 2006; Whiteley et al. 2012). In particular, delayed
intravenous t-PA is associated with a higher incidence of
intracranial hemorrhage, so earlier treatment is recom-
mended (Lees et al. 2010). In the present case, the patient
developed intracerebral hemorrhages 84 minutes after the
intravenous t-PA, strongly suggesting an association
between the hemorrhages and the thrombolytic ther-
apy. Although the exact pathogenesis of intracerebral
hemorrhages following intravenous t-PA in a patient
with Trousseau syndrome remains unknown, there are
at least two possible mechanisms from the findings in
the present patient. First, initial MRI showed several
FLAIR hyperintensities among the acute ischemic le-
sions on DWI, suggesting mixed ischemic lesions at
different developmental times. Development of FLAIR
hyperintensity within an acute ischemic lesion on DWI is
associated with an increased risk of hemorrhagic trans-
formation after thrombolysis (Kufner et al. 2013). There-
fore, the present patient may have had a potential risk of
hemorrhagic transformation at the FLAIR hyperintensities.
Second, the present patient developed cerebral hemor-
rhages in regions without visible ischemic tissue changes.
These extra-ischemic hemorrhages suggest pre-existingbrain pathology, especially cerebral amyloid angiopathy
(Trouillas and von Kummer 2006), and cerebral micro-
bleeds are related to cerebral amyloid angiopathy and
hypertensive microangiopathy (Vernooij et al. 2008). There-
fore, the present patient without microbleeds on MRI had a
lower risk of amyloid angiopathy-associated hemorrhages.
So why did the present patient with Trousseau syndrome
develop extra-ischemic hemorrhages? Although the old
age and great stroke severity may be associated with
intracranial hemorrhages following thrombolysis, we
think the other factors are also associated with intra-
cranial hemorrhages due to mulitiple and extra-
ischemic hemorrhages immediately after thrombolysis.
We hypothesize that micro-thromboembolism, micro-
metastasis, or micro-tumor embolism, which cannot be
detected on MRI, at areas remote from the acute ischemic le-
sions may have caused extra-ischemic hemorrhages (Bokuda
and Nozaki 2012). This suggests that intravenous t-PA
administration for acute ischemic stroke with Trousseau
syndrome may be associated with potential risks of intra-
cranial hemorrhage both in the ischemic lesions and in brain
areas remote from the infarcted tissue.
Some studies have compared intracerebral hemorrhage
rates following thrombolytic therapy for acute ischemic
stroke between patients with and without cancer, and
patients with cancer do not appear to have an increased
risk of intracranial hemorrhage (Masrur et al. 2011;
Murthy et al. 2013). However, there was no information
on coagulopathy in the study by Masrur et al., and only
40 (5.0%) of the 807 patients with cancer had coagulopa-
thy in the study by Murthy et al. Therefore, these studies
are not relevant to patients with a cancer-associated
hypercoagulable state (Trousseau syndrome). Little is
known about the risk of intracerebral hemorrhage follow-
ing thrombolysis in patients with Trousseau syndrome
because these patients generally have been excluded from
most clinical trials.
D-dimer levels are used in many studies as a direct indi-
cator of hypercoagulability (Grisold et al. 2009). A cancer-
associated hypercoagulable state represents a risk factor
for cerebral infarction, and D-dimer levels in cancer pa-
tients have been reported as significantly higher in pa-
tients with cerebral infarction due to cryptogenic stroke
mechanisms compared to conventional stroke mecha-
nisms (Kim et al. 2010; Schwarzbach et al. 2012). In par-
ticular, cancer patients with metastatic lesions are known
to show significantly increased D-dimer levels, and are
significantly more likely to develop cerebral infarction due
to cryptogenic stroke mechanisms (Kim et al. 2010; Hejna
et al. 1999). Thus, advanced cancer patients with crypto-
genic stroke with activation of the D-dimer level may be a
predictor of the diagnosis of Trousseau syndrome. There-
fore, careful confirmation with or without advanced can-
cer, cryptogenic stroke, and activation of the D-dimer
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intravenous thrombolysis.
Although the present patient had no identifiable contra-
indications to intravenous thrombolysis, perhaps thrombo-
lytic therapy should not have been used. We publish this
case report, due to the showing the attention of unexpected
extra-ischemic hemorrhages associated with Trousseau
syndrome despite the wrong decision on using thrombo-
lytic therapy in this patient. Clear guidelines are lacking on
intravenous t-PA administration for acute ischemic stroke
with Trousseau syndrome, and further investigations and
analyses of more case reports are needed.
Conclusion
This is the first known case report of multiple extra-
ischemic hemorrhages following intravenous t-PA in a
patient with Trousseau syndrome. The course of the
present case suggests that intravenous t-PA administration
for acute ischemic stroke with Trousseau syndrome may be
associated with a higher risk of intracerebral hemorrhage.
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